Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The HSP90 inhibitor onalespib potentiates Lu-177-DOTATATE therapy in neuroendocrine tumor cells
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Otolaryngology and Head and Neck Surgery.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medical Radiation Science.
2019 (English)In: International Journal of Oncology, ISSN 1019-6439, Vol. 55, no 6, p. 1287-1295Article in journal (Refereed) Published
Abstract [en]

Lu-177-DOTATATE was recently approved for the treatment of somatostatin receptor (SSTR)-positive neuroen-docrine tumors (NETs). However, despite impressive response rates, complete responses are rare. Heat shock protein 90 (HSP90) inhibitors have been suggested as suitable therapeutic agents for NETs, as well as a potential radiosensitizers. Consequently, the aim of this study was to investigate whether the HSP90-inhibitor onalespib could reduce NET cell growth and act as a radiosensitizer when used in combination with Lu-177-DOTATATE. The NET cell lines BON, NCI-H727 and NCI-H460, were first characterized with regards to Lu-177-DOTATATE uptake and sensitivity to onalespib treatment in monolayer cell assays. The growth inhibitory effects of the monotherapies and combination treatments were then examined in three-dimensional multicellular tumor spheroids. Lastly, the molecular effects of the treatments were assessed. Lu-177-DOTATATE uptake was observed in the BON and NCI-H727 cells, while the NCI-H460 cells exhibited no detectable uptake. Accordingly, Lu-177-DOTATATE reduced the growth of BON and NCI-H727 spheroids, while no effect was observed in the NCI-H460 spheroids. Onalespib reduced cell viability and spheroid growth in all three cell lines. Furthermore, the combination of onalespib and Lu-177-DOTATATE exerted synergistic therapeutic effects on the BON and NCI-H727 spheroids. Western blot analysis of BON spheroids revealed the downregulation of epidermal growth factor receptor (EGFR) and the upregulation of gamma H2A histone family member X (gamma H2AX) following combined treatment with onalespib and Lu-177-DOTATATE. Moreover, flow cytometric analyses revealed a two-fold increase in caspase 3/7 activity in the combination group. In conclusion, the findings of this study demonstrate that onalespib exerts antitumorigenic effects on NET cells and may thus be a feasible treatment option for NETs. Furthermore, onalespib was able to synergistically potentiate Lu-177-DOTATATE treatment in a SSTR-specific manner. The radiosensitizing mechanisms of onalespib involved the downregulation of EGFR expression and the induction of apoptosis. Consequently, the combination of onalespib and Lu-177-DOTATATE may prove to be a promising strategy with which to improve therapeutic responses in patients with NETs. Further studies investigating this strategy in vivo regarding the therapeutic effects and potential toxicities are warranted to expand these promising findings.

Place, publisher, year, edition, pages
SPANDIDOS PUBL LTD , 2019. Vol. 55, no 6, p. 1287-1295
Keywords [en]
neuroendocrine neoplasms, neuroendocrine tumors, peptide receptor radionuclide therapy, Lu-177-DOTATATE, Lutathera, heat shock protein 90, onalespib, AT13387, radiosensitization
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-400409DOI: 10.3892/ijo.2019.4888ISI: 000500272500009PubMedID: 31638190OAI: oai:DiVA.org:uu-400409DiVA, id: diva2:1382090
Funder
Swedish Cancer Society, CAN 2018/494Swedish Cancer Society, CAN2016/649Swedish Cancer Society, CAN 2015/1080Swedish Cancer Society, CAN 2015/385Swedish Research Council, 2013-30876-104113-30Available from: 2020-01-02 Created: 2020-01-02 Last updated: 2020-01-02Bibliographically approved

Open Access in DiVA

fulltext(1072 kB)11 downloads
File information
File name FULLTEXT01.pdfFile size 1072 kBChecksum SHA-512
02668a394f13a3d8c45b29e5cf03f022dbe264bba564a7144541bdcbb876dfc6a52e33ea2e5331ac43a402cf75e2476541505da9d5587603ec80d441b6108738
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lundsten, SaraSpiegelberg, DianaStenerlöw, BoNestor, Marika
By organisation
Medical Radiation ScienceOtolaryngology and Head and Neck Surgery
In the same journal
International Journal of Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 11 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 13 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf